The online version of this article (doi:https://doi.org/10.1186/s13058-017-0928-0) contains supplementary material, which is available to authorized users.
Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer development through increased prolactin levels and tamoxifen metabolism inhibition. Previous studies of breast cancer progression have focused on tamoxifen users, or have been limited by their small sample size and methodology. Therefore, we used UK population-based data to more robustly investigate the association between SSRI use and cancer-specific mortality.
A cohort of patients with newly-diagnosed breast cancer between 1998 and 2012 was selected from English cancer registries and linked to prescription records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used Cox regression models to calculate hazard ratios (HRs) comparing mortality between post-diagnostic SSRI users and non-users (using time-dependant covariates), after adjusting for demographics, comorbidities and pre-diagnosis use of hormone replacement therapy or oral contraceptives. We conducted several additional analyses to assess causality.
Our cohort included 23,669 breast cancer patients, of which 2672 used SSRIs and 3053 died due to their breast cancer during follow-up. After adjustment, SSRI users had higher breast cancer-specific mortality than non-users (HR = 1.27; 95% confidence interval (CI) 1.16, 1.40). However, this association was attenuated when restricting to patients with a prior history of depression (HR = 1.14; 95% CI 0.98, 1.33), and when comparing to users of other antidepressant medications (HR = 1.06; 95% CI 0.93, 1.20). There was some evidence of higher mortality among long-term SSRI users, even when restricting to patients with prior depression (HR = 1.54; 95% CI 1.03, 2.29).
In this large breast cancer cohort, SSRI use was associated with a 27% increase in breast cancer mortality. The cause of this is unknown; however, confounding by indication seems likely as it was largely attenuated when restricting to patients with prior depression, or when comparing SSRIs to other antidepressant medications. Clinicians should not be unduly concerned when prescribing SSRIs to breast cancer patients, but the increase in mortality among long-term SSRI users warrants further investigation.
Additional file 1: Appendix 1. presenting a list of generic and proprietary drug names used to identify SSRIs, Appendix 2 showing an illustration of the study design for selected analyses and Appendix 3 presenting the association between SSRI use and breast cancer mortality for specific medications (DOCX 65 kb)13058_2017_928_MOESM1_ESM.docx
Cancer Registration Statistics 2014, England. http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2014. Accessed 4 May 2017.
Globocan. Estimated Cancer Incidence, Mortaility and Prevelence Worldwide in 2012. ttp://globocan.iarc.fr. Accessed 30 May 2017.
Cancer survival in England: Patients diagnosed between 2010 and 2014 and followed up to 2015. http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinenglandadultsdiagnosed/2010and2014andfollowedupto2015. Accessed 24 Feb 2017.
Blair CK, Robien K, Inoue-Choi M, Rahn W, Lazovich D. Physical inactivity and risk of poor quality of life among elderly cancer survivors compared to women without cancer: the Iowa Women's Health Study. J Cancer Surviv Res Pract. 2016;10(1):103–12. CrossRef
Keetharuth A, Dixon S, Winter M, Clark P, Gutcher S, Horton M. Effects Of Cancer Treatment On Quality Of Life (ECTQOL): Final Results. Sheffield: Decision Support Unit, ScHARR; 2014.
National Institute for Health and Care Excellence. Depression in adults: recognition and management. London: NICE; 2009.
OpenPrescribing.net. https://openprescribing.net/. Accessed 2 June 2017.
Abbing-Karahagopian V, Huerta C, Souverein PC, de Abajo F, Leufkens HG, Slattery J, Alvarez Y, Miret M, Gil M, Oliva B, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. 2014;70(7):849–57. CrossRefPubMed
Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry. 2006;67(2):288–96. CrossRefPubMed
Shapovalov Y, Zettel M, Spielman SC, Amico-Ruvio SA, Kelly EA, Sipe GO, Dickerson IM, Majewska AK, Brown EB. Fluoxetine modulates breast cancer metastasis to the brain in a murine model. BMC Cancer. 2014;14:15. CrossRef
Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R. Early Breast Cancer Trialists Collaborative G. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67. CrossRef
Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010;340:8. CrossRef
Haque R, Shi JX, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, et al. Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors. J Natl Cancer Inst. 2016;108(3):8. CrossRef
National Cancer Data Repository. http://www.ncin.org.uk/collecting_and_using_data/national_cancer_data_repository/. Accessed 11 June 2017.
The Anatomical Therapeutic Chemical Classification System With Defined Daily Doses. http://www.who.int/classifications/atcddd/en/. Accessed 14 Oct 2017.
Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22(11):1931–43. CrossRefPubMed
Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340.
Bloechliger M, Ceschi A, Ruegg S, Jick SS, Meier CR, Bodmer M. Lifestyle factors, psychiatric and neurologic comorbidities, and drug use associated with incident seizures among adult patients with depression: a population-based nested case-control study. Eur J Epidemiol. 2016;31(11):1113–22. CrossRefPubMed
Lipsitch M, Tchetgen ET, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology (Cambridge, Mass). 2010;21(3):383–8. CrossRef
Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst. 2016;108(3).
Steele RJC, Brewster DH. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. BMJ . 2011;343.
Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006;98(24):1767–76. CrossRefPubMed
- Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study
Fabio Giuseppe Liberante
Chris R. Cardwell
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II